2024

1. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial

   The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810

2. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice

   Molecular Therapy, Vol. 32, Núm. 3, pp. 722-733

3. Consensus on surgical technique for sentinel lymph node dissection in cervical cancer

   International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 504-509

4. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

   Clinical Cancer Research, Vol. 30, Núm. 7, pp. 1319-1326

5. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

   Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

6. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

   Advances in Therapy

7. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

8. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

   Cancer Epidemiology, Vol. 92

9. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

   The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

10. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

11. How Molecular and Ancillary Tests Can Help in Challenging Cytopathology Cases: Insights from the International Molecular Cytopathology Meeting

    Journal of Molecular Pathology, Vol. 5, Núm. 2, pp. 228-237

12. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

13. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

14. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

    OncoImmunology, Vol. 13, Núm. 1

15. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

    Molecular Oncology

16. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

17. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

    Clinical Lymphoma, Myeloma and Leukemia

18. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

    Blood cancer discovery, Vol. 5, Núm. 1, pp. 21-33

19. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

20. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595